Merck touts a 60% price cut, but the drug is outdated and on the way out

Drugmakers have been lining up to tout new drug price policies lately, from deferring increases to freezing drug prices. Merck & Co. Inc. went a step further on Thursday, announcing a cap on average increases and cuts to some drug prices. The largest percentage cut announced was a 60% price reduction for its Zepatier treatment for hepatitis C.